FI121273B - FAS/APO1-reseptorien toiminnan modulaattorit - Google Patents

FAS/APO1-reseptorien toiminnan modulaattorit Download PDF

Info

Publication number: FI121273B
Authority: FI; Finland
Prior art keywords: protein; fas; mort; cells; sequence
Prior art date: 1994-12-15

Application number

FI972457A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI972457A0 (fi

FI972457L (fi

Inventor

David Wallach

Mark Boldin

Eugene Varfolomeev

Igor Mett

Original Assignee

Yeda Res & Dev

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-12-15

Filing date

1997-06-10

Publication date

2010-09-15

1994-12-15 Priority claimed from IL11200294A external-priority patent/IL112002A0/xx

1995-02-19 Priority claimed from IL112692A external-priority patent/IL112692A/en

1995-07-16 Priority claimed from IL11461595A external-priority patent/IL114615A0/xx

1997-06-10 Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev

1997-06-10 Publication of FI972457A0 publication Critical patent/FI972457A0/fi

1997-06-10 Publication of FI972457L publication Critical patent/FI972457L/fi

2010-09-15 Application granted granted Critical

2010-09-15 Publication of FI121273B publication Critical patent/FI121273B/fi

Links

101150028668 APO1 gene Proteins 0.000 title abstract description 5
108090000623 proteins and genes Proteins 0.000 claims abstract description 143
102000004169 proteins and genes Human genes 0.000 claims abstract description 133
239000013598 vector Substances 0.000 claims abstract description 54
210000004027 cell Anatomy 0.000 claims description 198
239000012634 fragment Substances 0.000 claims description 85
230000027455 binding Effects 0.000 claims description 77
108010077716 Fas-Associated Death Domain Protein Proteins 0.000 claims description 76
102000010579 Fas-Associated Death Domain Protein Human genes 0.000 claims description 72
230000000694 effects Effects 0.000 claims description 70
230000003834 intracellular effect Effects 0.000 claims description 69
238000000034 method Methods 0.000 claims description 60
102000005962 receptors Human genes 0.000 claims description 57
239000003446 ligand Substances 0.000 claims description 44
239000002299 complementary DNA Substances 0.000 claims description 38
108091028043 Nucleic acid sequence Proteins 0.000 claims description 27
102000014914 Carrier Proteins Human genes 0.000 claims description 19
241001465754 Metazoa Species 0.000 claims description 19
108091008324 binding proteins Proteins 0.000 claims description 19
241000700605 Viruses Species 0.000 claims description 18
239000000284 extract Substances 0.000 claims description 17
108020004414 DNA Proteins 0.000 claims description 16
240000004808 Saccharomyces cerevisiae Species 0.000 claims description 16
102000053642 Catalytic RNA Human genes 0.000 claims description 14
108090000994 Catalytic RNA Proteins 0.000 claims description 14
230000001413 cellular effect Effects 0.000 claims description 14
108091092562 ribozyme Proteins 0.000 claims description 14
239000000523 sample Substances 0.000 claims description 14
108091034117 Oligonucleotide Proteins 0.000 claims description 11
210000004881 tumor cell Anatomy 0.000 claims description 11
201000010099 disease Diseases 0.000 claims description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
230000009471 action Effects 0.000 claims description 9
238000010367 cloning Methods 0.000 claims description 9
108020004999 messenger RNA Proteins 0.000 claims description 9
150000001875 compounds Chemical class 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 7
108010001857 Cell Surface Receptors Proteins 0.000 claims description 5
230000000692 anti-sense effect Effects 0.000 claims description 5
239000000203 mixture Substances 0.000 claims description 5
230000036961 partial effect Effects 0.000 claims description 5
238000002105 Southern blotting Methods 0.000 claims description 4
230000002068 genetic effect Effects 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
238000004587 chromatography analysis Methods 0.000 claims description 2
230000004481 post-translational protein modification Effects 0.000 claims description 2
239000000825 pharmaceutical preparation Substances 0.000 claims 4
125000003275 alpha amino acid group Chemical group 0.000 claims 2
239000013543 active substance Substances 0.000 claims 1
239000012504 chromatography matrix Substances 0.000 claims 1
102000006240 membrane receptors Human genes 0.000 claims 1
238000010397 one-hybrid screening Methods 0.000 claims 1
230000001131 transforming effect Effects 0.000 claims 1
238000012258 culturing Methods 0.000 abstract 1
108010052621 fas Receptor Proteins 0.000 description 141
102000018823 fas Receptor Human genes 0.000 description 139
235000018102 proteins Nutrition 0.000 description 111
108020003175 receptors Proteins 0.000 description 55
108060008682 Tumor Necrosis Factor Proteins 0.000 description 37
230000014509 gene expression Effects 0.000 description 32
102000003390 tumor necrosis factor Human genes 0.000 description 31
108020001507 fusion proteins Proteins 0.000 description 29
102000037865 fusion proteins Human genes 0.000 description 28
238000003556 assay Methods 0.000 description 25
102000010170 Death domains Human genes 0.000 description 24
108050001718 Death domains Proteins 0.000 description 24
239000000427 antigen Substances 0.000 description 21
102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 20
150000001413 amino acids Chemical class 0.000 description 20
108091007433 antigens Proteins 0.000 description 19
102000036639 antigens Human genes 0.000 description 19
102100039556 Galectin-4 Human genes 0.000 description 17
230000001404 mediated effect Effects 0.000 description 15
101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 14
235000001014 amino acid Nutrition 0.000 description 14
230000001472 cytotoxic effect Effects 0.000 description 14
230000004568 DNA-binding Effects 0.000 description 13
238000011534 incubation Methods 0.000 description 13
230000003993 interaction Effects 0.000 description 13
230000035772 mutation Effects 0.000 description 13
239000002773 nucleotide Substances 0.000 description 13
125000003729 nucleotide group Chemical group 0.000 description 13
239000007787 solid Substances 0.000 description 13
239000004098 Tetracycline Substances 0.000 description 12
229960002180 tetracycline Drugs 0.000 description 12
229930101283 tetracycline Natural products 0.000 description 12
235000019364 tetracycline Nutrition 0.000 description 12
150000003522 tetracyclines Chemical class 0.000 description 12
101000801228 Homo sapiens Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 11
101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 11
231100000433 cytotoxic Toxicity 0.000 description 11
102000004196 processed proteins & peptides Human genes 0.000 description 11
108090000765 processed proteins & peptides Proteins 0.000 description 11
238000010396 two-hybrid screening Methods 0.000 description 11
102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 10
108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 10
102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 10
230000004913 activation Effects 0.000 description 10
230000030833 cell death Effects 0.000 description 10
239000013604 expression vector Substances 0.000 description 10
230000008569 process Effects 0.000 description 10
210000001519 tissue Anatomy 0.000 description 10
238000000211 autoradiogram Methods 0.000 description 9
238000001514 detection method Methods 0.000 description 9
238000001114 immunoprecipitation Methods 0.000 description 9
230000001105 regulatory effect Effects 0.000 description 9
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 9
238000013519 translation Methods 0.000 description 9
101150064015 FAS gene Proteins 0.000 description 8
102000005720 Glutathione transferase Human genes 0.000 description 8
108010070675 Glutathione transferase Proteins 0.000 description 8
108060001084 Luciferase Proteins 0.000 description 8
239000005089 Luciferase Substances 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 8
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 8
239000011324 bead Substances 0.000 description 8
230000022534 cell killing Effects 0.000 description 8
230000006870 function Effects 0.000 description 8
230000004927 fusion Effects 0.000 description 8
238000000338 in vitro Methods 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
239000013612 plasmid Substances 0.000 description 8
239000007790 solid phase Substances 0.000 description 8
102000003298 tumor necrosis factor receptor Human genes 0.000 description 8
108020004705 Codon Proteins 0.000 description 7
102000004190 Enzymes Human genes 0.000 description 7
108090000790 Enzymes Proteins 0.000 description 7
108010005774 beta-Galactosidase Proteins 0.000 description 7
210000004899 c-terminal region Anatomy 0.000 description 7
-1 e.g. Proteins 0.000 description 7
229940088598 enzyme Drugs 0.000 description 7
239000000047 product Substances 0.000 description 7
238000001890 transfection Methods 0.000 description 7
108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
102100026189 Beta-galactosidase Human genes 0.000 description 6
102100023995 Beta-nerve growth factor Human genes 0.000 description 6
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 6
102000018697 Membrane Proteins Human genes 0.000 description 6
108010052285 Membrane Proteins Proteins 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
239000000499 gel Substances 0.000 description 6
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical group OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
239000002609 medium Substances 0.000 description 6
238000012360 testing method Methods 0.000 description 6
102100026693 FAS-associated death domain protein Human genes 0.000 description 5
241000699670 Mus sp. Species 0.000 description 5
210000001744 T-lymphocyte Anatomy 0.000 description 5
230000003833 cell viability Effects 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
238000007796 conventional method Methods 0.000 description 5
230000003013 cytotoxicity Effects 0.000 description 5
231100000135 cytotoxicity Toxicity 0.000 description 5
239000012133 immunoprecipitate Substances 0.000 description 5
238000011065 in-situ storage Methods 0.000 description 5
238000001086 yeast two-hybrid system Methods 0.000 description 5
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 4
102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 4
102000000844 Cell Surface Receptors Human genes 0.000 description 4
108091026890 Coding region Proteins 0.000 description 4
XUJNEKJLAYXESH-UHFFFAOYSA-N Cysteine Chemical compound SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
241001529936 Murinae Species 0.000 description 4
108700008625 Reporter Genes Proteins 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
230000006907 apoptotic process Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000000969 carrier Substances 0.000 description 4
230000004186 co-expression Effects 0.000 description 4
230000006378 damage Effects 0.000 description 4
230000002255 enzymatic effect Effects 0.000 description 4
238000002955 isolation Methods 0.000 description 4
229910052751 metal Inorganic materials 0.000 description 4
239000002184 metal Substances 0.000 description 4
239000013642 negative control Substances 0.000 description 4
108010031345 placental alkaline phosphatase Proteins 0.000 description 4
238000012216 screening Methods 0.000 description 4
238000012546 transfer Methods 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
108020004635 Complementary DNA Proteins 0.000 description 3
108010001515 Galectin 4 Proteins 0.000 description 3
108010024636 Glutathione Proteins 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
101150055709 SNF1 gene Proteins 0.000 description 3
238000012300 Sequence Analysis Methods 0.000 description 3
108091023040 Transcription factor Proteins 0.000 description 3
102000040945 Transcription factor Human genes 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
231100000354 acute hepatitis Toxicity 0.000 description 3
238000001042 affinity chromatography Methods 0.000 description 3
230000002776 aggregation Effects 0.000 description 3
238000004220 aggregation Methods 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
239000012472 biological sample Substances 0.000 description 3
239000000872 buffer Substances 0.000 description 3
230000005889 cellular cytotoxicity Effects 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
230000034994 death Effects 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
239000012636 effector Substances 0.000 description 3
238000001914 filtration Methods 0.000 description 3
238000001415 gene therapy Methods 0.000 description 3
229960003180 glutathione Drugs 0.000 description 3
208000006454 hepatitis Diseases 0.000 description 3
210000004408 hybridoma Anatomy 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
238000013198 immunometric assay Methods 0.000 description 3
230000006698 induction Effects 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
150000002739 metals Chemical class 0.000 description 3
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
239000000758 substrate Substances 0.000 description 3
230000000451 tissue damage Effects 0.000 description 3
231100000827 tissue damage Toxicity 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
101000835846 Arabidopsis thaliana Sucrose nonfermenting 4-like protein Proteins 0.000 description 2
102000003910 Cyclin D Human genes 0.000 description 2
108090000259 Cyclin D Proteins 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
101150009006 HIS3 gene Proteins 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
102000004195 Isomerases Human genes 0.000 description 2
108090000769 Isomerases Proteins 0.000 description 2
108010047294 Lamins Proteins 0.000 description 2
102000006835 Lamins Human genes 0.000 description 2
102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
238000000636 Northern blotting Methods 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
206010040070 Septic Shock Diseases 0.000 description 2
101710120037 Toxin CcdB Proteins 0.000 description 2
206010046865 Vaccinia virus infection Diseases 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
239000012190 activator Substances 0.000 description 2
230000002411 adverse Effects 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
230000003302 anti-idiotype Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
238000000376 autoradiography Methods 0.000 description 2
230000008827 biological function Effects 0.000 description 2
230000036755 cellular response Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
230000006854 communication Effects 0.000 description 2
238000004891 communication Methods 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
230000002950 deficient Effects 0.000 description 2
230000002939 deleterious effect Effects 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
238000010166 immunofluorescence Methods 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000031146 intracellular signal transduction Effects 0.000 description 2
238000002372 labelling Methods 0.000 description 2
210000005053 lamin Anatomy 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
238000004020 luminiscence type Methods 0.000 description 2
239000006166 lysate Substances 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
238000001466 metabolic labeling Methods 0.000 description 2
238000000386 microscopy Methods 0.000 description 2
PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
239000013641 positive control Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
238000000163 radioactive labelling Methods 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
230000009467 reduction Effects 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
230000007017 scission Effects 0.000 description 2
230000036303 septic shock Effects 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
230000011664 signaling Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
201000000596 systemic lupus erythematosus Diseases 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
108091006106 transcriptional activators Proteins 0.000 description 2
230000010474 transient expression Effects 0.000 description 2
102000035160 transmembrane proteins Human genes 0.000 description 2
108091005703 transmembrane proteins Proteins 0.000 description 2
208000007089 vaccinia Diseases 0.000 description 2
230000035899 viability Effects 0.000 description 2
239000013603 viral vector Substances 0.000 description 2
FFEARJCKVFRZRR-QABOKHJMSA-N (2S)-2-amino-4-methyl(30S)sulfanylbutanoic acid Chemical compound N[C@@H](CC[30S]C)C(=O)O FFEARJCKVFRZRR-QABOKHJMSA-N 0.000 description 1
KTPDNYVWXJTUKG-UHFFFAOYSA-O 1-methyl-2-[2-(2-phenyl-1h-indol-3-yl)ethenyl]quinolin-1-ium Chemical compound C1=CC2=CC=CC=C2[N+](C)=C1\C=C\C(C1=CC=CC=C1N1)=C1C1=CC=CC=C1 KTPDNYVWXJTUKG-UHFFFAOYSA-O 0.000 description 1
HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
102000012440 Acetylcholinesterase Human genes 0.000 description 1
108010022752 Acetylcholinesterase Proteins 0.000 description 1
108010000239 Aequorin Proteins 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
101150013553 CD40 gene Proteins 0.000 description 1
210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
206010006895 Cachexia Diseases 0.000 description 1
102100035882 Catalase Human genes 0.000 description 1
108010053835 Catalase Proteins 0.000 description 1
101710104316 Cell surface-binding protein Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
241001131785 Escherichia coli HB101 Species 0.000 description 1
101710127053 FAS-associated death domain protein Proteins 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
102100022624 Glucoamylase Human genes 0.000 description 1
108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
102000000587 Glycerolphosphate Dehydrogenase Human genes 0.000 description 1
108010041921 Glycerolphosphate Dehydrogenase Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101100099884 Homo sapiens CD40 gene Proteins 0.000 description 1
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
108010047357 Luminescent Proteins Proteins 0.000 description 1
102000006830 Luminescent Proteins Human genes 0.000 description 1
208000030289 Lymphoproliferative disease Diseases 0.000 description 1
102000013460 Malate Dehydrogenase Human genes 0.000 description 1
108010026217 Malate Dehydrogenase Proteins 0.000 description 1
108010059724 Micrococcal Nuclease Proteins 0.000 description 1
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical group OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
108091008604 NGF receptors Proteins 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
108010053210 Phycocyanin Proteins 0.000 description 1
108010004729 Phycoerythrin Proteins 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
239000012083 RIPA buffer Substances 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
108010046334 Urease Proteins 0.000 description 1
229940022698 acetylcholinesterase Drugs 0.000 description 1
DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
210000001789 adipocyte Anatomy 0.000 description 1
108010004469 allophycocyanin Proteins 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
238000004873 anchoring Methods 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
229960005475 antiinfective agent Drugs 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
238000005415 bioluminescence Methods 0.000 description 1
230000029918 bioluminescence Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000010267 cellular communication Effects 0.000 description 1
230000007248 cellular mechanism Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
238000004737 colorimetric analysis Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000007123 defense Effects 0.000 description 1
229940009976 deoxycholate Drugs 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
230000029087 digestion Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
230000002900 effect on cell Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000006862 enzymatic digestion Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
239000011521 glass Substances 0.000 description 1
125000003712 glycosamine group Chemical group 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
230000012010 growth Effects 0.000 description 1
230000007773 growth pattern Effects 0.000 description 1
108060003552 hemocyanin Proteins 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
102000047715 human FAS Human genes 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
230000010262 intracellular communication Effects 0.000 description 1
230000004068 intracellular signaling Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
238000011005 laboratory method Methods 0.000 description 1
229910052747 lanthanoid Inorganic materials 0.000 description 1
150000002602 lanthanoids Chemical class 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
108020001756 ligand binding domains Proteins 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000009630 liquid culture Methods 0.000 description 1
210000005229 liver cell Anatomy 0.000 description 1
HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
201000001268 lymphoproliferative syndrome Diseases 0.000 description 1
239000000463 material Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
231100000587 neutral red assay Toxicity 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
229940054441 o-phthalaldehyde Drugs 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229960003330 pentetic acid Drugs 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
210000001539 phagocyte Anatomy 0.000 description 1
RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
238000000751 protein extraction Methods 0.000 description 1
230000009145 protein modification Effects 0.000 description 1
230000004850 protein–protein interaction Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
235000013024 sodium fluoride Nutrition 0.000 description 1
239000011775 sodium fluoride Substances 0.000 description 1
CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 1
241000894007 species Species 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
238000007447 staining method Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1
208000016261 weight loss Diseases 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
230000029663 wound healing Effects 0.000 description 1
238000003158 yeast two-hybrid assay Methods 0.000 description 1
229910000166 zirconium phosphate Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
- C12N9/641—Cysteine endopeptidases (3.4.22)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
- C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Toxicology (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Biotechnology (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Transmitters (AREA)
Peptides Or Proteins (AREA)
Measurement Of Current Or Voltage (AREA)
Secondary Cells (AREA)

FI972457A 1994-12-15 1997-06-10 FAS/APO1-reseptorien toiminnan modulaattorit FI121273B (fi)

Applications Claiming Priority (8)

Application Number	Priority Date	Filing Date	Title
IL11200294		1994-12-15
IL11200294A IL112002A0 (en)	1994-05-11	1994-12-15	Modulatiors of tnf/ngf superfamily receptors, their preparation and use
IL112692A IL112692A (en)	1995-02-19	1995-02-19	ANTIBODIES TO PROTEIN WHICH BINDS TO Fas-R
IL11269295		1995-02-19
IL11461595A IL114615A0 (en)	1995-07-16	1995-07-16	Modulators of the function of fas receptors and other proteins
IL11461595		1995-07-16
PCT/US1995/016542 WO1996018641A1 (fr)	1994-12-15	1995-12-14	Modulateurs de la fonction des recepteurs de fas/ap01
US9516542		1995-12-14

Publications (3)

Publication Number	Publication Date
FI972457A0 FI972457A0 (fi)	1997-06-10
FI972457L FI972457L (fi)	1997-06-10
FI121273B true FI121273B (fi)	2010-09-15

Family

ID=27271687

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI972457A FI121273B (fi)	1994-12-15	1997-06-10	FAS/APO1-reseptorien toiminnan modulaattorit

Country Status (17)

Country	Link
EP (1)	EP0871645B1 (fr)
JP (1)	JP3787355B2 (fr)
KR (1)	KR100536394B1 (fr)
CN (1)	CN1105725C (fr)
AT (1)	ATE377073T1 (fr)
AU (1)	AU706401B2 (fr)
CA (1)	CA2207815C (fr)
CY (1)	CY2586B2 (fr)
DE (1)	DE69535634T2 (fr)
DK (1)	DK0871645T3 (fr)
ES (1)	ES2292172T3 (fr)
FI (1)	FI121273B (fr)
MX (1)	MX9704501A (fr)
NO (1)	NO324725B1 (fr)
PT (1)	PT871645E (fr)
UA (1)	UA58489C2 (fr)
WO (1)	WO1996018641A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL114615A0 (en)	1995-07-16	1995-11-27	Yeda Res & Dev	Modulators of the function of fas receptors and other proteins
US6060238A (en) *	1995-02-13	2000-05-09	The Regents Of The University Of Michigan	Method and composition for regulating apoptosis
US7097972B1 (en)	1995-02-13	2006-08-29	Regents Of The University Of Michigan	Method and composition for regulating apoptosis
US6015665A (en) *	1995-02-13	2000-01-18	The Regents Of The University Of Michigan	Method and composition for regulating apoptosis
AU755662B2 (en) *	1995-02-22	2002-12-19	Yeda Research And Development Co. Ltd.	Modulators of regulatory proteins
ES2242195T3 (es) *	1995-02-22	2005-11-01	YEDA RESEARCH & DEVELOPMENT COMPANY, LTD.	Moduladores de proteinas reguladoras.
US6747138B1 (en)	1995-04-03	2004-06-08	Regents Of The University Of Michigan	Methods and compositions for regulating Fas-associated apoptosis
US7807783B1 (en)	1995-04-03	2010-10-05	The Regents Of The University Of Michigan	Methods and compositions for regulating FAS-associated apoptosis
US6399327B1 (en)	1995-07-16	2002-06-04	Yeda Research And Development Co. Ltd.	Modulators of the function of FAS receptors and other proteins
US6911526B2 (en) *	1996-07-22	2005-06-28	The Trustees Of Columbia University In The City Of New York	Compounds that inhibit the interaction between signal-transducing proteins and the GLGF (PDZ/DHR) domain and uses thereof
EP0842665A3 (fr) *	1996-11-14	2002-12-18	Smithkline Beecham Corporation	Protéases d'apoptose de type enzyme de conversion d'interleukine-1-bèta et leurs agonistes
US5969102A (en) *	1997-03-03	1999-10-19	St. Jude Children's Research Hospital	Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
PT977846E (pt) *	1997-04-25	2002-11-29	Wyeth Corp	Isoformas de morti neuronal
WO1999000499A1 (fr) *	1997-06-26	1999-01-07	Chiron Corporation	Proteine humaine interagissant avec fadd (fip)
US7833529B1 (en)	1999-01-07	2010-11-16	Zymogenetics, Inc.	Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US6015712A (en) *	1999-07-19	2000-01-18	Isis Pharmaceuticals Inc.	Antisense modulation of FADD expression
SI1436003T1 (sl)	2001-05-24	2010-02-26	Zymogenetics Inc	TACI-imunoglobulinski fuzijski proteini
US6743630B2 (en)	2002-03-06	2004-06-01	The Trustees Of Columbia University In The City Of New York	Method of preparing a protein array based on biochemical protein-protein interaction
WO2007019575A2 (fr)	2005-08-09	2007-02-15	Zymogenetics, Inc.	Procedes destines au traitement des malignites des lymphocytes b au moyen d'une molecule de fusion taci-ig
AR059025A1 (es)	2005-08-09	2008-03-12	Zymogenetics Inc	Metodos para el tratamiento y prevencion de proliferacion de celulas anormales utilizando moleculas de fusion taci
AR060935A1 (es)	2006-05-15	2008-07-23	Ares Trading Sa	Metodos para tratar enfermedades autoinmunes utilizando una molecula de fusion taci- ig

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NO178777C (no) *	1994-05-09	1996-05-29	Kvaerner Eng	Varmeveksler
US7807783B1 (en) *	1995-04-03	2010-10-05	The Regents Of The University Of Michigan	Methods and compositions for regulating FAS-associated apoptosis
US5674734A (en) *	1995-05-18	1997-10-07	President And Fellows Of Harvard College	Cell death protein

1995
- 1995-12-14 CA CA2207815A patent/CA2207815C/fr not_active Expired - Lifetime
- 1995-12-14 JP JP51932496A patent/JP3787355B2/ja not_active Expired - Lifetime
- 1995-12-14 WO PCT/US1995/016542 patent/WO1996018641A1/fr active IP Right Grant
- 1995-12-14 EP EP95944148A patent/EP0871645B1/fr not_active Expired - Lifetime
- 1995-12-14 MX MX9704501A patent/MX9704501A/es active IP Right Grant
- 1995-12-14 UA UA97063391A patent/UA58489C2/uk unknown
- 1995-12-14 PT PT95944148T patent/PT871645E/pt unknown
- 1995-12-14 ES ES95944148T patent/ES2292172T3/es not_active Expired - Lifetime
- 1995-12-14 AU AU46022/96A patent/AU706401B2/en not_active Expired
- 1995-12-14 DE DE69535634T patent/DE69535634T2/de not_active Expired - Lifetime
- 1995-12-14 DK DK95944148T patent/DK0871645T3/da active
- 1995-12-14 CN CN95196789A patent/CN1105725C/zh not_active Expired - Lifetime
- 1995-12-14 KR KR1019970703992A patent/KR100536394B1/ko not_active Expired - Lifetime
- 1995-12-14 AT AT95944148T patent/ATE377073T1/de active
1997
- 1997-06-10 FI FI972457A patent/FI121273B/fi not_active IP Right Cessation
- 1997-06-12 NO NO19972716A patent/NO324725B1/no not_active IP Right Cessation
2007
- 2007-11-20 CY CY0700017A patent/CY2586B2/xx unknown

Also Published As

Publication number	Publication date
AU4602296A (en)	1996-07-03
FI972457A0 (fi)	1997-06-10
FI972457L (fi)	1997-06-10
EP0871645B1 (fr)	2007-10-31
CN1169729A (zh)	1998-01-07
KR100536394B1 (ko)	2006-04-21
MX9704501A (es)	1997-10-31
CN1105725C (zh)	2003-04-16
PT871645E (pt)	2007-11-14
EP0871645A4 (fr)	1999-11-24
DK0871645T3 (da)	2007-12-03
ES2292172T3 (es)	2008-03-01
NO972716L (no)	1997-07-11
CY2586B2 (en)	2009-11-04
CA2207815C (fr)	2011-03-29
JP3787355B2 (ja)	2006-06-21
DE69535634D1 (de)	2007-12-13
UA58489C2 (uk)	2003-08-15
JPH10510712A (ja)	1998-10-20
DE69535634T2 (de)	2008-08-28
WO1996018641A1 (fr)	1996-06-20
NO972716D0 (no)	1997-06-12
ATE377073T1 (de)	2007-11-15
CA2207815A1 (fr)	1996-06-20
EP0871645A1 (fr)	1998-10-21
AU706401B2 (en)	1999-06-17
HK1007248A1 (en)	1999-04-09
NO324725B1 (no)	2007-12-03

Publication	Publication Date	Title
FI121273B (fi)	2010-09-15	FAS/APO1-reseptorien toiminnan modulaattorit
US8236507B2 (en)	2012-08-07	Modulators of TNF receptor associated factor (TRAF), their preparation and use
JP3980641B2 (ja)	2007-09-26	Ｆａｓ受容体およびほかのタンパク質の機能のモジュレーター
US20070166787A1 (en)	2007-07-19	Modulators of regulatory proteins
WO1996018641A9 (fr)	1996-08-22	Modulateurs de la fonction des recepteurs de fas/ap01
EP0813419B1 (fr)	2005-05-25	Modulateurs de proteines regulatoires
IL109632A (en)	2007-03-08	Modulators of the function of tnf receptors
JP4351389B2 (ja)	2009-10-28	Ｔｎｆ／ｎｇｆレセプターファミリーおよびほかのタンパク質のレセプター機能調節物質
US7323548B2 (en)	2008-01-29	Modulators of the function of FAS/APO1 receptors
RU2241747C2 (ru)	2004-12-10	Молекула днк, кодирующая полипептид, способный связываться с внутриклеточным доменом рецептора лиганда fas(fas-ic), полипептид, способ его получения, вектор, способ модуляции действия лиганда fas-r на клетки (варианты), фармацевтическая композиция (варианты), спрособ выделения и идентификации белка
US7108999B1 (en)	2006-09-19	Modulators of the function of FAS/AP01 receptors
RU2235779C2 (ru)	2004-09-10	Последовательность днк, кодирующая полипептид, который связывается с mort-1 (варианты), полипептид (варианты) и способ его получения, вектор, способ модулирования действия лиганда fas-r или tnf на клетки (варианты), способ обработки клеток, способ выделения и идентификации белков, способ модулирования индуцируемого mort-1 действия или индуцируемого mort-1 связывающим белком действия на клетки
AU767967B2 (en)	2003-11-27	Modulators of TNF receptor associated factor (TRAF), their preparation and use
JP2009148285A (ja)	2009-07-09	Ｔｎｆ／ｎｇｆレセプターファミリーおよびほかのタンパク質のレセプター機能調節物質
IL112692A (en)	2012-01-31	ANTIBODIES TO PROTEIN WHICH BINDS TO Fas-R
IL126428A (en)	2010-02-17	Modulators of tnf receptor associated factor (traf), their preparation and use
AU5834599A (en)	2000-03-02	Modulators of regulatory proteins

Legal Events

Date	Code	Title	Description
2010-09-15	FG	Patent granted	Ref document number: 121273 Country of ref document: FI
2016-01-20	MA	Patent expired

Date

Code

Title

Description